Vivos Therapeutics Inc Forecast, price target & analysts
Vivos Therapeutics Inc Target price 2026 - Analyst rating & recommendation
Vivos Therapeutics Inc Classifications & Recommendation
Vivos Therapeutics Inc Price Target
| Target Price | $2.55 |
| Price | $0.15 |
| Potential |
1,652.58%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Vivos Therapeutics Inc 2027 .
The average Vivos Therapeutics Inc target price is $2.55.
This is
1,652.58%
register free of charge
$3.26
2,137.11%
register free of charge
$0.76
420.62%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Vivos Therapeutics Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vivos Therapeutics Inc stock has an average upside potential 2027 of
1,652.58%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 17.44 | 22.84 |
| 16.03% | 30.96% | |
| EBITDA Margin | -106.54% | -91.55% |
| 51.20% | 14.07% | |
| Net Margin | -121.39% | -88.04% |
| 63.78% | 27.47% |
6 Analysts have issued a sales forecast Vivos Therapeutics Inc 2026 . The average Vivos Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Vivos Therapeutics Inc EBITDA forecast 2026. The average Vivos Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Vivos Therapeutics Inc Analysts have issued a net profit forecast 2026. The average Vivos Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.06 | -1.38 |
| 7.21% | 33.01% | |
| P/E | negative | |
| EV/Sales | 0.49 |
5 Analysts have issued a Vivos Therapeutics Inc forecast for earnings per share. The average Vivos Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Vivos Therapeutics Inc...
Current Vivos Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Jun 04 2026 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Apr 22 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 17 2026 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Dec 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 17 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Sep 09 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Jun 04 2026 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Apr 22 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 17 2026 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Dec 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 17 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Sep 09 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Apr 15 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
